1Elias D, Sideris L, Pocard M, et al. Results of RO resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol, 2004, 11 (3):274-280.
2Curley SA. Outcomes after surgical treatment of colorectal cancer liver metastases. Semin Oncol, 2005,32 (6 Suppl 9):109-111.
3Elias D, Liberale G, Vernerey D, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol, 2005,12(11) :900-909.
4Ferrero A, Polastri R, Muratore A, et al. Extensive resections for colorectal liver metastases. J Hepatobiliary Pancrea Surg, 2004, 11(2):92-96.
5Stewart GD, O'Suilleabhain CB, Madhavan KK, et al.The extent of resection influences outcome following hepatectomy for colorectal liver metastases. Eur J Surg Oncol. 2004,30(4) :370-376.
6Comella P, Gambardella A, Farris A, et al. A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.Crit Rev Oncol Hematol. 2005, 53(2) :133-139.
7Schmoll H J, Cassidy J. Integrating oxaliplatin into the management of colorectal cancer. Oncologist, 2001, 6(Suppl 4) :24-28.
8Borner MM, Dietrich D, Stupp R, et al. Phase Ⅱ study of capecitahine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol, 2002,20(7) :1759-1766.
9Cassidy J, Tabernero J, Twelves C, et al. XELOX(capecitahine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol, 2004,22(11) :2084-2091.
10Santini D, Vincenzi B, La Cesa A, et al. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Oncology, 2005, 69(1):27-34.
